HSRC REPORT: This study extrapolates empirical cost data from Sub-saharan African firms to consider the conditions under which domestic production of drugs in a facility in Sub-saharan Africa would be feasible and profitable as a business enterprise, while at the same time, able to promote better access to quality medicines, at a price more affordable than international prices for local consumers.